105963-46-0
105963-46-0 structure
- Name: TOK-8801
- Chemical Name: 3,6,6-trimethyl-N-(2-phenylethyl)-5H-imidazo[2,1-b][1,3]thiazole-2-carboxamide
- CAS Number: 105963-46-0
- Molecular Formula: C17H21N3OS
- Molecular Weight: 315.43300
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2016-09-18 22:31:08
- Modify Date: 2024-01-02 19:59:24
-
TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator.
| Name | 3,6,6-trimethyl-N-(2-phenylethyl)-5H-imidazo[2,1-b][1,3]thiazole-2-carboxamide |
|---|---|
| Synonyms |
Tok 8801
Imidazo[2,1-b]thiazole-2-carboxamide,5,6-dihydro-3,6,6-trimethyl-N-(2-phenylethyl) N-(2-Phenylethyl)-3,6,6-trimethyl-5,6-dihydroimidazo(2,1-b)thiazole-2-carboxamide TOK-8801 |
| Description | TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator. |
|---|---|
| Related Catalog | |
| In Vitro | TOK-8801 is a synthesized dihydroimidazothiazole carboxamide and is under development as an immunomodulator. TOK-8801 augments the in vitro anti-SRBC PFC response of murine splenocytes in a bell-shaped manner. The stimulatory effect of TOK-8801 is observed at concentrations of 2.5×10-7 to 2.5×10-5 M and is diminished at 10-4 M. The cell-viability is not altered during the culture with TOK-8801 at any doses used in this experiment (10-7 to 10-4 M). TOK-8801 enhances the 3H-TdR uptake of these responses in a bell-shaped manner, and effective concentrations of TOK-8801 are 10-7 to 10-5 M[1]. |
| In Vivo | The anti-SRBC PFC response per spleen, which is prominently lowered by restraint-stress (P<0.05), is significantly restored by the administration of TOK-8801 (0.5 mg/kg, P<0.05). The number of total splenic lymphocytes in restraint-stress is decreased, but there are no significant changes in the number of total splenic lymphocytes by the treatment with TOK-8801[1]. When TOK-8801 is administered orally at doses of 0.1 to 10 mg/kg, the number of plaque forming cell (PFC) significantly decreases or tends to decrease. Treatment of TOK-8801 at doses of 0.1 to 1 mg/kg causes significant suppression in the delayed-type hypersensitivity (DTH) reaction induced in high responder[2]. |
| Cell Assay | Spleen cells (2×105) or thymus cells (2×105) from BALB/c mice are cultured with Con A (1 or 5 μg/mL) or LPS (10 μg/mL) in 0.2 mL of RPMI-1640 medium containing 5% FCS using round-bottomed microculture plates with 96 wells for 2 days and are pulsed with 0.5 μCi of 3H-TdR for an additional 18 hr. Then, cells are harvested on glass fiber fillters, and 3H-TdR incorporation is measured in a liquid scintillation counter. TOK-8801 is added at the initiation of the culture[1]. |
| Animal Admin | Male BDFI mice are used in this study. Control mice are maintained without food or water while counterparts are under the condition of restraint-stress. On the next day, the mice are immunized with 5×108 SRBC intraperitoneally. Immediately, 24 hr and 48 hr after the immunization, TOK-8801 is orally given at doses of 0.02, 0.1 and 0.5 mg/kg/day. All administrations are done after a starvation for 6 hr. Four days after the immunization, splenic anti SRBC PFC are assayed[1]. |
| References |
| Density | 1.23g/cm3 |
|---|---|
| Molecular Formula | C17H21N3OS |
| Molecular Weight | 315.43300 |
| Exact Mass | 315.14100 |
| PSA | 78.12000 |
| LogP | 2.53380 |
| Index of Refraction | 1.639 |
| Storage condition | 2-8℃ |